The Central government on Wednesday, 15 July launched Phase-III of the Biomedical Research Career Programme (BRCP) with a total outlay of ₹1,500 crore, aimed at expanding fellowships, scaling research grants, and translating scientific discoveries into practical healthcare solutions. The announcement was made through an official statement from the Ministry of Science and Technology.

Funding Breakdown

Of the total corpus, ₹1,000 crore will be contributed by the Department of Biotechnology, while the remaining ₹500 crore comes from the London-based Wellcome Trust, marking a significant international philanthropic commitment to India's biomedical ecosystem. The blended public-private funding model is designed to reduce dependence on government allocations alone and signal India's credibility as a global research destination.

What the Programme Aims to Achieve

According to Union Minister of State for Science and Technology and Earth Sciences, Dr. Jitendra Singh, Phase-III is designed to nurture a globally competitive biomedical research workforce spanning basic scientists, clinician-researchers, public health experts, science communicators, and research managers. The programme also seeks to create greater opportunities for interdisciplinary and collaborative research across institutions.

Dr. Singh added that the initiative is expected to attract fresh philanthropic and international partnerships, multiplying the impact of India's investments in biomedical science. Notably, the launch event included interactions with researchers whose careers were shaped by earlier phases of the programme, along with presentations on its scientific achievements and long-term impact.

India's Bioeconomy: The Bigger Picture

The minister highlighted that India's bioeconomy has expanded nearly twenty-fold — from $10 billion in 2014 to more than $195 billion in 2025 — and is projected to reach $300 billion by 2030. India currently hosts nearly 12,000 biotechnology startups and has emerged as one of the world's leading vaccine manufacturers, steadily reinforcing its position as a global biotechnology hub.

Dr. Singh described biotechnology as 'the defining force behind India's next phase of economic growth, scientific advancement and global competitiveness,' underscoring the strategic importance the government places on the sector.

Call for Greater Private and Philanthropic Participation

The minister also called on philanthropic institutions and industry players to step up engagement, arguing that while India possesses abundant scientific talent and innovative ideas, sustained financial partnerships remain essential for converting research into technologies, diagnostics, and affordable healthcare solutions. This comes amid a broader push by the Centre to reduce the translation gap between laboratory discoveries and market-ready healthcare products.

What Comes Next

Phase-III builds on the foundation laid by earlier iterations of the programme, with a sharper focus on research translation and ecosystem-building. Observers will watch whether the expanded fellowship base and international funding partnership produce measurable outcomes in patent filings, clinical trials, and commercialised health innovations — metrics that earlier phases were not always benchmarked against publicly.